|
|
| Nogueira,M.C.; Azevedo,A.M.; Pereira,S.C.M.; Ferreira,J.L.; Lerner,D.; Lobo,A.M.G.; Tavares,R.C.B.S.; Tabak,D.G.; Lorenzi,N.; Renault,I.Z.; Bouzas,L.F.S.. |
| Allogeneic stem cell transplantation has been increasingly performed for a variety of hematologic diseases. Clinically significant acute graft-versus-host disease (GVHD) occurs in 9 to 50% of patients who receive allogeneic grafts, resulting in high morbidity and mortality. There is no standard therapy for patients with acute GVHD who do not respond to steroids. Studies have shown a possible benefit of anti-TNF-a (infliximab)for the treatment of acute GVHD. We report here on the outcomes of 10 recipients of related or unrelated stem cell transplants who received 10 mg/kg infliximab, iv, once weekly for a median of 3.5 doses (range: 1-6) for the treatment of severe acute GVHD and who were not responsive to standard therapy. All patients had acute GVHD... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Infliximab; Graft-versus-host disease; Hematopoietic stem cell transplantation. |
| Ano: 2007 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007001200005 |
| |
